Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-04-04
2006-04-04
Housel, James (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023700, C536S028600, C536S028700, C536S029100, C514S04400A, C514S046000, C514S043000, C514S023000, C514S027000, C424S189100, C424S185100, C424S192100, C424S093100, C435S091100
Reexamination Certificate
active
07022830
ABSTRACT:
Aspects of the present invention relate to the discovery of a novel hepatitis C virus (HCV) isolate. Embodiments include HCV peptides, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic acids and peptides, as well as methods of making and using the aforementioned compositions including, but not limited to, diagnostics and medicaments for the treatment and prevention of HCV infection.
REFERENCES:
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4950647 (1990-08-01), Robins et al.
patent: 5350671 (1994-09-01), Houghton et al.
patent: 5371017 (1994-12-01), Houghton et al.
patent: 5372928 (1994-12-01), Miyamura et al.
patent: 5585258 (1996-12-01), Houghton et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5597691 (1997-01-01), Houghton et al.
patent: 5670152 (1997-09-01), Weiner et al.
patent: 5670153 (1997-09-01), Weiner et al.
patent: 5679342 (1997-10-01), Houghton et al.
patent: 5683864 (1997-11-01), Houghton et al.
patent: 5698390 (1997-12-01), Houghton et al.
patent: 5712087 (1998-01-01), Houghton et al.
patent: 5712088 (1998-01-01), Houghton et al.
patent: 5712145 (1998-01-01), Houghton et al.
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5728520 (1998-03-01), Weiner et al.
patent: 5756312 (1998-05-01), Weiner et al.
patent: 5766845 (1998-06-01), Weiner et al.
patent: 5767097 (1998-06-01), Tam
patent: 5847101 (1998-12-01), Okayama et al.
patent: 5856437 (1999-01-01), Miyamura et al.
patent: 5863719 (1999-01-01), Houghton et al.
patent: 5879904 (1999-03-01), Brechot et al.
patent: 5885799 (1999-03-01), Houghton et al.
patent: 5932556 (1999-08-01), Tam
patent: 5942234 (1999-08-01), Ralston et al.
patent: 5959092 (1999-09-01), Miyamura et al.
patent: 5968775 (1999-10-01), Houghton et al.
patent: 5989905 (1999-11-01), Houghton et al.
patent: 6027729 (2000-02-01), Houghton et al.
patent: 6056961 (2000-05-01), Lavie et al.
patent: 6060068 (2000-05-01), Doyle et al.
patent: 6063380 (2000-05-01), Chedid et al.
patent: 6063772 (2000-05-01), Tam
patent: 6071693 (2000-06-01), Cha et al.
patent: 6074816 (2000-06-01), Houghton et al.
patent: 6074846 (2000-06-01), Ralston et al.
patent: 6074852 (2000-06-01), Ralston et al.
patent: 6096541 (2000-08-01), Houghton et al.
patent: 6130326 (2000-10-01), Ramasamy et al.
patent: 6150087 (2000-11-01), Chien
patent: 6150337 (2000-11-01), Tam
patent: 6153421 (2000-11-01), Yanagi et al.
patent: 6171782 (2001-01-01), Houghton et al.
patent: 6190864 (2001-02-01), Cha et al.
patent: 6194140 (2001-02-01), Houghton et al.
patent: 6214583 (2001-04-01), Cha et al.
patent: 6235888 (2001-05-01), Pachuk et al.
patent: 6274148 (2001-08-01), Ralston et al.
patent: 6297370 (2001-10-01), Cha et al.
patent: 6303292 (2001-10-01), Weiner et al.
patent: 6312889 (2001-11-01), Houghton et al.
patent: 6514731 (2003-02-01), Valenzuela et al.
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 6555114 (2003-04-01), Leroux-Roels et al.
patent: 6653125 (2003-11-01), Donnelly et al.
patent: 2002/0165172 (2002-11-01), Sallberg et al.
patent: 2002/0183508 (2002-12-01), Maertens et al.
patent: 2002/0187945 (2002-12-01), Tam
patent: 2003/0007977 (2003-01-01), Wheeler et al.
patent: 2003/0008274 (2003-01-01), Maertens et al.
patent: 2003/0032005 (2003-02-01), Maertens et al.
patent: 2003/0044774 (2003-03-01), Valenzuela et al.
patent: 2003/0064360 (2003-04-01), Maertens et al.
patent: 0 318 216 (1989-05-01), None
patent: 0 388 232 (1990-09-01), None
patent: 0 414 475 (1991-02-01), None
patent: 0 450 931 (1996-06-01), None
patent: 0 543 924 (1997-06-01), None
patent: 0 842 947 (1998-05-01), None
patent: 0 693 687 (1999-07-01), None
patent: 0 556 292 (1999-12-01), None
patent: 1 034 785 (2000-09-01), None
patent: 0 318 216 (2001-08-01), None
patent: 0 398 748 (2002-01-01), None
patent: WO 91/15575 (1991-10-01), None
patent: WO 92/19743 (1992-11-01), None
patent: WO 93/00365 (1993-01-01), None
patent: WO 93/06126 (1993-04-01), None
patent: WO 94/16737 (1994-08-01), None
patent: WO 96/09805 (1996-04-01), None
patent: WO 96/28162 (1996-09-01), None
patent: WO 96/33739 (1996-10-01), None
patent: WO 97/12043 (1997-04-01), None
patent: WO 97/26883 (1997-07-01), None
patent: WO 97/47358 (1997-12-01), None
patent: WO 98/16184 (1998-04-01), None
patent: WO 98/16186 (1998-04-01), None
patent: WO 98/30223 (1998-07-01), None
patent: WO 98/34640 (1998-08-01), None
patent: WO 98/37180 (1998-08-01), None
patent: WO 99/04008 (1999-01-01), None
patent: WO 99/28482 (1999-06-01), None
patent: WO 99/28482 (1999-06-01), None
patent: WO 00/44388 (2000-08-01), None
patent: WO 01/38360 (2001-05-01), None
patent: WO 01/96875 (2001-12-01), None
patent: WO 02/13855 (2002-02-01), None
patent: WO 02/14362 (2002-02-01), None
patent: WO 03/031588 (2003-04-01), None
patent: WO 03/031588 (2003-04-01), None
Hulgren et al. Hepatology 1998, vol. 79, pp. 2381-2391.
Encke et al. J. Immunol. 1998, vol. 161, pp. 4917-4923.
BLASTIN 2.2.9., May 1, 2004.
Kumar et al., “Sequence, expression and reconstitution of an HCV genome from a British isolate derived from a single blood donation,” Journal of Viral Hepatitis, 7:459-465, (2000).
NCBI, Genbank, M32084. Hepatitis C Virus . . . [gi:329875] Aug. 2, 1993.
Andre et al., “Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp 120 Sequence with Optimized Codon Usage,”Journal of Virology, 72(2):1497-1503 (1998).
DATABASE GENBANK [Online] Dec. 2, 1994, retrieved from NCBI Database accession No. 106434, XP002278035.
DATABASE REGISTRY [Online] No. 511600-20-7, XP02278058 abstract & WO 03/031588A, Apr. 17, 2003, Seq ID No. 1, 10 and 11 claims.
Lazdina et al., “Humoral and CD4+ T helper (Th) cell responses to the hepatitis C virus non-structural 3 NS3) protein: NS3 primes Th 1-like responses more effectively as a DNA-based immunogen than as a recombinant protein,”Journal of General Virology, 82:1299-1308 (2001).
Abrignani, et al., “Perspectives for a vaccine against hepatitis C virus,”Journal of Hepatology, 3(1): 259-263 (1999).
Bartenschlager, et al., “Substrate Determinants for Clevage in cis and in trans by the Hepatitis C Virus NS3 Proteinase,”Journal of Virology, 69(1):198-205 (1995).
Fang, et al., “Ribavirin enhancement of the hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level,”Journal of Hepatology, 33(5):791-798 (2000).
Grakoui, et al., “A second hepatitis C virus-encolded proteinase,”Proc. Natl. Acad. Sci. USA, 90:10583-10587 (1993).
Hultgren et al., “The antiviral compound ribavirin modulates the Thelper (TH)1/Th2 subset balance in hepatitis B and C virus-specific immune responses,”J. Gene. Virol.,79(10):2381-2391 (1998).
Kumar, et al., “Hepatitis C virus genomic RNA for polyprotein gene,”Journal of Hepatology, 7:459-465 (2000).
Sallberg, et al., “A Hepatitis C Virus Non-Structural NS3/4A Fusion Gene,” U.S. Appl. No. 09/930,591, filed Aug. 15, 2001.
Tam, et al., “The immunomodulatory effects of ribavirin: Recent findings,” International Antiviral News, pp. 99-101 (1999).
Walsh, et al., “Update on chronic viral hepatitis,”Postgrad. Med. J.,77:498-505 (2001).
Zhang et al., “Interferon-alpha treatment induces delayed CD4 proliferative responses to the hepatitis C virus nonstructural protein 3 regardless of the outcome of thereapy,”Journal of Infectious Diseases, 175(6):1294-1301 (1997).
Zhang et al., “Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the hos-derived GOR protein,”Clin. Exp. Immunol.,96(3):403-409 (1994).
Chen et al., “Detection of Hepatitis C Virus RNA in the Cell Fraction of Saliva Before and After Oral Surgey,”J. Med. Virol.,43:223-226 (1995).
Chiang et al., “Enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response by ribavirin correlates with the increased level of IL-2,”Vaccine Strategies Against M
Housel James
Knobbe Martens Olson & Bear LLP
Li Bao Qun
Tripep AB
LandOfFree
Hepatitis C virus codon optimized non-structural NS3/4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus codon optimized non-structural NS3/4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus codon optimized non-structural NS3/4A... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3571411